Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1476-5551
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia ; day:14 ; month:5 ; year:2019 ; pages:1-5
Leukemia ; (14.5.2019), 1-5

Creator
Stilgenbauer, Stephan
Aurran Schleinitz, Thérèse
Eichhorst, Barbara
Lang, Fabian
Offner, Fritz
Rossi, Jean-François
Schroyens, Wilfried
Neste, Eric Van Den
Ysebaert, Loïc
Wangenheim, Ute von
Ursula Kress, Uta
Blum, Petra
Zenz, Thorsten
Contributor
SpringerLink (Online service)

DOI
10.1038/s41375-019-0475-z
URN
urn:nbn:de:101:1-2019062422222668607798
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Stilgenbauer, Stephan
  • Aurran Schleinitz, Thérèse
  • Eichhorst, Barbara
  • Lang, Fabian
  • Offner, Fritz
  • Rossi, Jean-François
  • Schroyens, Wilfried
  • Neste, Eric Van Den
  • Ysebaert, Loïc
  • Wangenheim, Ute von
  • Ursula Kress, Uta
  • Blum, Petra
  • Zenz, Thorsten
  • SpringerLink (Online service)

Other Objects (12)

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Management of relapsed-refractory diffuse large B cell lymphoma

Management of relapsed-refractory diffuse large B cell lymphoma

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

Related objects